LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

ABBV

217.16

+0.73%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

Inicio・Lista de Acciones・CareDx Inc

CareDx Inc

Cerrado

SectorSanidad

22.28 1.64

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

21.48

Máximo

22.29

Métricas clave
By Trading Economics
Ingresos	6.9M 2.8M
Ventas	9.3M 118M
P/B Media del Sector	14.645 49.888
BPA	0.34
Margen de beneficios	2.387
Empleados	761
EBITDA	5.6M 7.1M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+22.81% upside

Dividendos
By Dow Jones
Próximas Ganancias	5 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	59M 1.2B
Apertura anterior	20.64
Cierre anterior	22.28

Noticias sobre sentimiento de mercado

By Acuity

36%

64%

100 / 344 Clasificación en Healthcare

CareDx Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 jun 2026, 20:30 UTC

Ganancias

Palo Alto Networks 3Q Revenue Rises as Customers Beef Up Cyber Defenses

2 jun 2026, 23:58 UTC

Charlas de Mercado

Australia's Consumer Sector Expected to Be Stung by Housing Downturn -- Market Talk

2 jun 2026, 23:46 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

2 jun 2026, 23:46 UTC

Charlas de Mercado

Nikkei May Rise as AI Demand Hopes Continue -- Market Talk

2 jun 2026, 23:41 UTC

Charlas de Mercado

Oil Rises Amid Signs of U.S.-Iran Peace Talks Stalling -- Market Talk

2 jun 2026, 23:01 UTC

Adquisiciones, fusiones, absorciones

ACCC Says Owner of Metro Petroleum Brand to Buy the 41 Sites

2 jun 2026, 23:01 UTC

Adquisiciones, fusiones, absorciones

ACCC Says Ampol Must Sell 41 Retail Fuel Sites to an Approved Purchaser

2 jun 2026, 23:00 UTC

Adquisiciones, fusiones, absorciones

Australia's Competition Regulator Approves Ampol's Purchase of EG Australia With Conditions

2 jun 2026, 22:57 UTC

Charlas de Mercado

Australian Dollar Could Fall Following 1Q GDP Data -- Market Talk

2 jun 2026, 22:50 UTC

Charlas de Mercado

Ulta Beauty Says TikTok Shop Will Provide 'Halo' Effect -- Market Talk

2 jun 2026, 21:07 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

2 jun 2026, 21:07 UTC

Charlas de Mercado

Tokenized Assets Need Access to Digital-Finance Plumbing -- Market Talk

2 jun 2026, 21:00 UTC

Ganancias

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

2 jun 2026, 20:46 UTC

Ganancias

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 jun 2026, 20:38 UTC

Ganancias

GitLab Stock Rises as the Software Company Raises Guidance on AI Business Momentum -- Barrons.com

2 jun 2026, 20:21 UTC

Ganancias

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 jun 2026, 20:12 UTC

Ganancias

Palo Alto Stock Jumps on Strong Earnings -- Barrons.com

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks 3Q Product Rev $594M

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks Sees FY26 Next-Generation Security ARR $8.9B-$8.95B

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks Raises FY26 View To Adj EPS $3.77-Adj EPS $3.79 >PANW

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks 3Q Subscription and Support Rev $2.41B

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks Sees FY26 Remaining Performance Obligation $20.9B-$21B

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks Sees 4Q Rev $3.345B-$3.355B >PANW

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks Sees 4Q Adj EPS 96c-Adj EPS 98c >PANW

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks on Track to Achieve 40% Adj Free Cash Flow Margin in FY28

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks Raises FY26 View To Rev $11.415B-$11.425B >PANW

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks 3Q Remaining Performance Obligation $18.4B

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks 3Q Adj EPS 85c >PANW

2 jun 2026, 20:05 UTC

Ganancias

Palo Alto Networks 3Q Loss $177M >PANW

Comparación entre iguales

Cambio de precio

CareDx Inc previsión

Precio Objetivo

By TipRanks

22.81% repunte

Estimación a 12 Meses

Media 28 USD 22.81%

Máximo 28 USD

Mínimo 28 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CareDx Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para CareDx Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

100 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de CareDx Inc

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.